Published in final edited form as:

J Inorg Biochem. 2012 November ; 116C: 204–214. doi:10.1016/j.jinorgbio.2012.06.017.

Cytotoxic Hydrophilic Iminophosphorane Coordination Compounds of d⁸ Metals. Studies of their Interactions with DNA and HSA

Monica Carreira^a, Rubén Calvo-Sanjuán^b, Mercedes Sanaú^c, Xiangbo Zhao^a, Richard S. Magliozzo^a, Isabel Marzo^b, and María Contel^{*,a}

^aDepartment of Chemistry, Brooklyn College and The Graduate Center, The City University of New York, Brooklyn, NY, 11210, US

^bDepartment of Biochemistry and Molecular and Cellular Biology, University of Zaragoza, 50009, Spain

^cDepartamento de Química Inorgánica, Universidad de Valencia, Burjassot, Valencia, 46100, Spain

Abstract

The synthesis and characterization of a new water-soluble N,N-chelating iminophosphorane ligand TPA=N-C(O)-2-NC₅H₄ (N,N-IM) (**1**) and its d⁸ (Au^{III}, Pd^{II} and Pt^{II}) coordination complexes are reported. The structures of cationic [AuCl₂(N,N-IM)] ClO₄ (**2**) and neutral [MCl₂(N,N-IM)] M = Pd (**3**), Pt(**4**) complexes were determined by X-ray diffraction studies or by means of density-functional calculations. While the Pd and Pt compounds are stable in mixtures of DMSO/H₂O over 4 days, the gold derivative (**2**) decomposes quickly to TPA=O and previously reported neutral gold(III) compound [AuCl₂(N,N-H)] **5** (containing the chelating N,N- fragment HN-C(O)-2-NC₅H₄). The cytotoxicities of complexes **2–5** were evaluated *in vitro* against human Jurkat-T acute lymphoblastic leukemia cells and DU-145 human prostate cancer cells. Pt (**4**) and Au compounds (**2** and **5**) are more cytotoxic than cisplatin to these cell lines and to cisplatin-resistant Jurkat sh-Bak cell lines and their cell death mechanism is different from that of cisplatin. All the compounds show higher toxicity against leukemia cells when compared to normal human T-lymphocytes (PBMC). The interaction of the Pd and Pt compounds with calf thymus and plasmid (pBR322) DNA is different from that of cisplatin. All compounds bind to human serum albumin (HSA) faster than cisplatin (measured by fluorescence spectroscopy). Weak and stronger binding interactions were found for the Pd (**3**) and Pt (**4**) derivatives by isothermal titration calorimetry. Importantly, for the Pt (**4**) compounds the binding to HSA was reversed by addition of a chelating agent (citric acid) and by a decrease in pH.

Keywords

cytotoxic; leukemia; prostate cancer; iminophosphoranes; water-soluble; platinum; palladium; gold

© 2012 Elsevier Inc. All rights reserved.

*Corresponding author: *Department of Chemistry, Brooklyn College and The Graduate Center, The City University of New York, Brooklyn, NY, 11210, US*, Fax: +17189514607, mariacontel@brooklyn.cuny.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

Cisplatin combination chemotherapy is the cornerstone of treatment for many cancers. Cisplatin and the follow-on drugs carboplatin and oxaliplatin are used to treat 40–80% of cancer patients [1]. The high effectiveness of cisplatin in the treatment of several types of tumors is severely hindered by some clinical problems such as normal tissue toxicity and the frequent occurrence of initial and acquired resistance to the drug [1–5]. A growing number of so-called “cisplatin rule-breaker” compounds have been reported [3–5] along with some Pt(IV) pro-drugs that can be photoactivated by visible light [7]. These findings have paved the way for studying other metal-based chemotherapeutic compounds [3] including relevant examples of gold [9], palladium [10], titanium [11], ruthenium [12], osmium [13] and iron complexes [14].

We and others have reported on the biological [15–18] and catalytic [19–21] applications of iminophosphorane or iminophosphine derivatives of gold(III) (selected examples in Fig. 1) [15,16]. The main advantage of iminophosphorane ligands is that they provide a C,N- or N,N-backbone that stabilizes the resulting square-planar d^8 transition metal complex. An extra advantage is that the P atom in the PR_3 fragment can be used as a “spectroscopic marker” to study the *in vitro* stability (and oxidation state) by $^{31}P\{^1H\}$ NMR [16]. Gold(III) organometallic complexes (with a pincer C,N-iminophosphorane ligand) displayed a high cytotoxicity *in vitro* against human ovarian cancer and leukemia cell lines while being less toxic to normal T-lymphocytes by a mode of action different from that of cisplatin [15,16]. The compounds did not interact with DNA [15]. ROS (reactive oxygen species) production at the mitochondrial level was a critical step in the cytotoxic effect of these compounds [15]. We wanted to increase the hydrophilicity of this type of IM (iminophosphorane) ligands and also to explore the biological activity of other d^8 metal (Pd(II) and Pt(II)) IM complexes. We envisioned an iminophosphorane N,N- chelating ligand as an ideal platform to confer stability to d^8 transition metal centers while simplifying the synthetic steps required to prepare organometallic compounds (avoiding transmetallation for metals not prone to easy C-H bond activation). We had used such a strategy to prepare gold(III) coordination catalysts for C-C and C-heteroatom bond formation [20]. The challenge here was the incorporation of a water-soluble phosphine in the skeleton of the ligand since it is well known that IMs in contact with water or polar solvents break down to the corresponding amine and phosphine oxide [22].

By the use of a picolinamide and water-soluble TPA (1,3,5-triaza-7-phosphaadamantane) phosphine through the Pomerantz method [23], we prepared a stabilized water-soluble N,N-chelating iminophosphorane ligand $TPA=N-C(O)-2-NC_5H_4$ **1** (Scheme 1). To the best of our knowledge, this is the first water-soluble iminophosphorane reported. We describe here the preparation (Scheme 1), characterization, stability in solution and study of the cytotoxic properties *in vitro* of its coordination complexes containing Au(III), Pd(II) and Pt(II) centers. The study of the interactions of these complexes with different biomolecules (DNA and Human Serum Albumin HSA) is also reported and compared to that of cisplatin.

2. Experimental Section

2.1. Materials and Methods

All manipulations involving air-free syntheses were performed using standard Schlenk-line techniques under an argon atmosphere or in a glove-box MBraun MOD System. Solvents were purified by use of a PureSolv purification unit from Innovative Technology, Inc. The phosphine substrate TPA was purchased from Sigma-Aldrich, $K[AuCl_4]$, $PtCl_2$ and $AgClO_4$ were purchased from Strem chemicals and used without further purification. $[PdCl_2(COD)]$

[24] and $[\text{AuCl}_2(\text{HN}-\text{C}(\text{O})-2-\text{NC}_5\text{H}_4)]$ **5** [25] were prepared as previously reported. NMR spectra were recorded in a Bruker AV400 (^1H NMR at 400 MHz, ^{13}C NMR at 100.6 MHz, ^{31}P NMR at 161.9 MHz). Chemical shifts (δ) are given in ppm using CDCl_3 , d^6 -DMSO or D_2O as solvent, unless otherwise stated. ^1H and ^{13}C chemical shifts were measured relative to solvent peaks considering TMS (tetramethylsilane) = 0 ppm; $^{31}\text{P}\{^1\text{H}\}$ was externally referenced to H_3PO_4 (85%). Infrared spectra (4000 – 250 cm^{-1}) were recorded on a Nicolet 6700 FT-IR spectrophotometer on KBr pellets. Elemental analyses were performed on a Perkin Elmer 2400 CHNS/O Analyzer, Series II. Mass spectra HR-ESI (High-resolution electrospray ionization) or MALDI (Matrix-assisted laser desorption/ionization) were performed on an Agilent Analyzer or a Bruker Analyzer. Conductivity was measured in an OAKTON pH/conductivity meter in CH_3CN solution (10^{-3}M). Circular Dichroism spectra were recorded using a Chirascan CD Spectrometer equipped with a thermostated cuvette holder. Electrophoresis experiments were carried out in a Bio-Rad Mini sub-cell GT horizontal electrophoresis system connected to a Bio-Rad Power Pac 300 power supply. Photographs of the gels were taken with an Alpha Innotech FluorChem 8900 camera. Fluorescence intensity measurements were carried out on a PTI QM-4/206 SE Spectrofluorometer (PTI, Birmingham, NJ) with right angle detection of fluorescence using a 1 cm path length quartz cuvette. ITC measurements were carried out at $25.0 (\pm 0.2)^\circ\text{C}$ on a MicroCal VP-ITC calorimeter.

2.2. Synthesis

TPA=N-C(O)-2-NC₅H₄ (N,N-IM) (1)—TPA (0.157 g, 1.0 mmol) and picolinamide (0.122 g, 1.0 mmol) were placed in a Schlenk flask under nitrogen. Dry, degassed THF (15 mL) was added and to this solution, tBuDAD (0.230 g, 1.0 mmol) in dry and degassed THF (4 mL) was added dropwise at 0°C . The reaction was left stirring at RT for 15 hours. After this period, the yellow reaction mixture was colourless with some white precipitate. The solvent was reduced *in vacuo* to a minimum ($< 2\text{ mL}$) and Et_2O (10 mL) was added, giving a white solid that was filtered and dried *in vacuo*. Yield: 0.254 g (93%). Anal. Calcd for $\text{C}_{12}\text{H}_{16}\text{N}_5\text{OP}$ (277.11): C, 51.98; H, 5.82; N, 25.26. Found: C, 51.76; H, 5.79; N, 25.24. MS (ESI+) $[m/z]$: 278.12 $[\text{M}]^+$. $^{31}\text{P}\{^1\text{H}\}$ NMR: δ -29.4 (s, CDCl_3), -31.4 (s, DMSO- d_6), -24.8 (s, D_2O). ^1H NMR (CDCl_3): δ 8.68 (1H, d, $^3J_{\text{HH}}$ 4 Hz, NCH), 8.10 (1H, d, $^3J_{\text{HH}}$ 8 Hz, C(O)CCH), 7.75 (1H, t, $^3J_{\text{HH}}$ 8 Hz, C(O)CCHCH), 7.37 (1H, t, $^3J_{\text{HH}}$ 7 Hz, NCHCH), 4.35 (6H, d, $^2J_{\text{PH}}$ 8 Hz, PCH_2N), 4.42 (AB system, 6H, NCH_2N). $^{13}\text{C}\{^1\text{H}\}$ NMR (CDCl_3): δ 177.7 (s, C=O), 152.0 (s, C(O)C(N)(CH)), 149.1 (s, NCH), 136.7 (s, C(O)CCHCH), 125.4 (s, NCHCH), 123.5 (s, C(O)CCH), 72.8 (d, J_{PC} 9 Hz, NCH_2N), 52.7 (d, J_{PC} 46 Hz, PCH_2N). IR (cm^{-1}): ν 1582 (C=O), 1360 (P=N).

$[\text{AuCl}_2(\text{N,N-IM})]\text{ClO}_4$ (2)—To $\text{K}[\text{AuCl}_4]$ (0.057 g, 0.15 mmol) in dry MeCN (10 mL), AgClO_4 (0.068 g, 0.33 mmol) in dry MeCN (2 mL) was added and the reaction mixture was stirred in the dark for 30 min, after which it was filtered through Celite (to remove AgCl). **1** (0.042 g, 0.15 mmol) in CH_2Cl_2 (1 mL) was added and the yellow solution became instantly brown. After 50 min stirring, the reaction mixture was again filtered through celite (to remove KClO_4) and then the solvent was reduced *in vacuo* to a minimum. Upon addition of Et_2O (10 mL), a red-brown solid was obtained, which was washed with MeCN ($< 1\text{ mL}$ at a time) and Et_2O and dried *in vacuo*. Yield: 0.050 g (52%). MS (HR-ESI+) $[m/z]$: 544.0126 $[\text{M}]^+$. $^{31}\text{P}\{^1\text{H}\}$ NMR: δ 6.5 (s, DMSO- d_6), 5.7 (s, CD_3CN). ^1H NMR (CD_3CN): δ 9.39 (1H, d, $^3J_{\text{HH}}$ 6 Hz, NCH), 8.60 (1H, t, $^3J_{\text{HH}}$ 8 Hz, C(O)CCHCH), 8.19 (2H, m, C(O)CCH + NCHCH), 5.08 (6H, $^2J_{\text{PH}}$ 10 Hz, PCH_2N), 4.52 (AB system, 6H, NCH_2N). $^{13}\text{C}\{^1\text{H}\}$ NMR (CD_3CN): δ 146.1 (s, C(O)CCHCH), 132.2 (s, NCHCH), 130.4 (s, C(O)CCH), 71.2 (d, J_{PC} 9 Hz, NCH_2N), 54.5 (d, J_{PC} 37 Hz, PCH_2N) (unable to identify remaining carbons due to poor signal to noise ratio because of the low solubility and stability of compound). IR

(cm^{-1}): ν 1654 (C=O), 1292 (P=N), 1089 (ClO_4), 254 and 302 (M-Cl). Conductivity: $\Lambda = 97.8 \mu\text{S/cm}$.

[PdCl₂(N,N-IM)] (3)—[PdCl₂(COD)] (0.041 g, 0.15 mmol) and **1** (0.042 g, 0.15 mmol) were dissolved in dry and degassed CH₂Cl₂ (4 mL) and left to react for 3 hours at room temperature after which an orange precipitate formed. The solvent was then reduced to a minimum *in vacuo* and upon addition of Et₂O a pale orange solid was obtained which was washed twice with CHCl₃ and dried *in vacuo*. Yield: 0.035 g (52%). Anal. Calcd for C₁₂H₁₆Cl₂N₅OPPd (454.59): C, 31.71; H, 3.55; N, 15.41. Found: C, 31.63; H, 3.23; N, 15.41. MS (MALDI+) [m/z]: 420.0 [M-Cl]. ³¹P{¹H} NMR(DMSO-d₆): δ -6.4 (s). ¹H NMR (DMSO-d₆): δ 9.03 (1H, d, ³J_{HH} 5 Hz, NCH), 8.20 (1H, t, ³J_{HH} 7 Hz, C(O)CCHCH), 7.85 (1H, d, ³J_{HH} 8 Hz, C(O)CCH), 7.78 (1H, t, ³J_{HH} 7 Hz, NCHCH), 4.39 (AB system, 6H, NCH₂N), 4.42 (6H, ²J_{PH} 8 Hz, PCH₂N). ¹³C{¹H} NMR (DMSO-d₆): δ 173.8 (s, C=O), 150.5 (s, C(O)C(N)(CH)), 149.1 (s, NCH), 141.4 (s, C(O)CCHCH), 129.6 (s, NCHCH), 127.1 (s, C(O)CCH), 71.4 (d, J_{PC} 9 Hz, NCH₂N), 53.7 (d, J_{PC} 37 Hz, PCH₂N). IR (cm^{-1}): ν 1659 (C=O), 1290 (P=N), 290 (M-Cl).

[PtCl₂(N,N-IM)] (4)—PtCl₂ (0.080 g, 0.30 mmol) and **1** (0.083 g, 0.30 mmol) were refluxed for 2 days in a mixture of CH₂Cl₂ (10 mL) and acetone (2 mL). The reaction mixture was filtered through Celite to remove any unreacted PtCl₂, giving a yellow solution. The solvent was reduced to a minimum *in vacuo* and upon addition of Et₂O a yellow solid was obtained, which was washed twice with CHCl₃ and dried *in vacuo*. Yield: 0.025 g (15%). Anal. Calcd for C₁₂H₁₆Cl₂N₅OPPt (542.01): C, 26.53; H, 2.97; N, 12.89. Found: C, 25.90; H, 2.48; N, 13.16. MS (MALDI+) [m/z]: 502.1 [M-Cl]. ³¹P{¹H} NMR(DMSO-d₆): δ -4.4 (s). ¹H NMR (DMSO-d₆): δ 9.35 (1H, d, ³J_{HH} 5 Hz, NCH), 8.33 (1H, t, ³J_{HH} 8 Hz, C(O)CCHCH), 7.83 (2H, d, ³J_{HH} 8 Hz, C(O)CCH + NCHCH), 4.95 (6H, d, ²J_{PH} 8 Hz, PCH₂N), 4.42 (6H, s, NCH₂N). ¹³C{¹H} NMR (DMSO-d₆): δ 173.8 (s, C=O), 151.1 (s, C(O)C(N)(CH)), 150.0 (s, NCH), 141.9 (s, C(O)CCHCH), 130.6 (s, NCHCH), 128.0 (s, C(O)CCH), 71.3 (d, J_{PC} 7 Hz, NCH₂N), 55.1 (d, J_{PC} 50 Hz, PCH₂N). IR (cm^{-1}): ν 1667 (C=O), 1282 (P=N), 290 (M-Cl).

2.3. X-Ray crystallography

Single crystals of **3** and **4** (see details below) were mounted on a glass fiber in a random orientation. Data collection was performed at room temperature on a Kappa CCD diffractometer using graphite monochromated Mo-K α radiation ($\lambda=0.71073 \text{ \AA}$). Space group assignments were based on systematic absences, E statistics and successful refinement of the structures. The structures were solved by direct methods with the aid of successive difference Fourier maps and were refined using the SHELXTL 6.1 software package. All non-hydrogen atoms were refined anisotropically. Hydrogen atoms were assigned to ideal positions and refined using a riding model. Details of the crystallographic data are given in Table S1 (Supplementary Information (SI)). These data can be obtained free of charge from The Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/data_request/cif. (CCDC 858692 for compound **3**, and 858693 for compound **4**).

3: Crystals of **3** (orange prisms with approximate dimensions $0.28 \times 0.24 \times 0.24 \text{ mm}$) were obtained from a solution of **3** in DMSO by slow diffusion of Et₂O at RT. **4:** Crystals of **4** (yellow prisms with approximate dimensions $0.26 \times 0.24 \times 0.20 \text{ mm}$) were obtained from a solution of **4** in DMSO by slow diffusion of Et₂O at RT.

2.4. Computational Methods

All calculations reported here were carried out using the Gaussian 09 program package. [26] All gas phase structures were optimized at the B3LYP/6-31G* level of density functional

theory (DFT) in combination with relativistic effective-core potential cc-pVDZ-PP for heavy metals (platinum and gold) where appropriate. Aqueous solution structures are found with PCM (polarizable continuum model) full geometry optimization at the B3LYP/6-31G* level of DFT in combination with relativistic effective-core potential ccpVTZ-PP for heavy metals (platinum and gold) where appropriate. Computed frequencies were positive, in all cases, indicating that the optimized structures represent the minima of ground-state potential-energy surfaces. In addition, a simple visual comparison of computed IR spectra with experimental spectra was performed to further validate reliability of computed structures.

2.5. Determination of Compound Cytotoxicity

The human T-cell leukemia Jurkat (clone E6.1) from the ATCC collection and the prostate carcinoma DU-145 were routinely cultured in RPMI 1640 medium supplemented with 5% FCS (fetal calf serum), L-glutamine and penicillin/streptomycin (hereafter, complete medium). Blood samples from healthy donors were obtained from the Banco de Sangre y Tejidos de Aragón. All subjects gave written informed consent and the Ethical Committee of Aragón approved the study. Normal T-lymphocytes (peripheral blood mononuclear cells: PBMC) were freshly isolated by Ficoll-Paque density centrifugation. After isolation, normal PBMC were kept in RPMI 1640 medium supplemented with 10% decompartmented FCS, L-glutamine and penicillin/streptomycin. Jurkat cells lacking Bak were generated using RNA interference techniques, as described previously [27]. For toxicity assays, Jurkat cells (5×10^5 cells/mL), DU145 cells (1×10^5 cells/mL) or normal T-lymphocytes PBMC (3×10^6 cells/mL) were seeded in flat-bottom 96-well plates (100 μ L/well) in complete medium. DU145 cells were allowed to attach prior to addition of cisplatin or tested compounds. Compounds were added at different concentrations in triplicate. Cells were incubated with cisplatin or compounds for 24 h and then cell proliferation was determined by a modification of the MTT-reduction method [28]. Total cell number and cell viability were determined by the Trypan-blue exclusion test. Apoptosis/necrosis hallmarks were analyzed by simultaneously measuring the mitochondrial membrane potential, exposure of phosphatidylserine and 7-AAD uptake. In brief, 2.5×10^5 cells in 200 μ L were incubated in ABB (140mM NaCl, 2.5 mM CaCl_2 , 10 mM Hepes/NaOH, pH 7.4), with either 5nM $\text{DiOC}_6(3)$ or 60nM TMRE (both from Molecular Probes) at 37°C for 10 minutes. AnnexinV-PE or AnnexinV-FITC (Invitrogen) at a concentration of 0.5 μ g/mL or 7-AAD (50ng/ μ L) was added to samples and incubated at 37 °C for an additional 15 minutes. In all cases, cells from each well were diluted to 1 mL with ABB to be counted by flow cytometry (FACScan, BD Bioscience, Spain).

2.6. Interaction of metal complexes with CT DNA by Circular Dichroism Spectroscopy

Stock solutions (5 mM) of each complex were freshly prepared in DMSO- H_2O (1:99) prior to use. Aliquots were added to a solution of CT (Calf Thymus) DNA (195 μ M) also freshly prepared in buffer (5 mM Tris/HCl, 50 mM NaClO_4 , pH = 7.39) to achieve molar ratios of 0.1, 0.25, 0.5, 1.0 drug/DNA while keeping a total volume of 3 mL. The samples were incubated at 37 °C for 20 h in the dark. All CD spectra of DNA and of the DNA-drug adducts were recorded at 25 °C over a range 220–320 nm and finally corrected with a blank and noise reduction. Noise reduction was performed using the Savitzky-Golay smoothing filter incorporated in the Chirascan software. The spectra are given in molar ellipticity (millidegrees).

2.7. Interaction of metal complexes with plasmid (pBR322) DNA by Electrophoresis (Mobility Shift Assay)

10 μ L aliquots of pBR322 plasmid DNA (20 μ g/mL) in buffer (5 mM Tris/HCl, 50 mM NaClO_4 , pH = 7.39) were incubated with molar ratios between 0.25 and 4.0 of the

compounds at 37 °C for 20 h in the dark. Samples of free DNA and cisplatin-DNA adduct were prepared as controls. After the incubation period, 2 µL of loading dye were added to the samples and of these mixtures, 7 µL were finally loaded onto the 1 % agarose gel. The samples were separated by electrophoresis for 1.5 h at 80 V in Tris-acetate/EDTA buffer (TAE). Afterwards, the gel was stained for 30 min with a solution of GelRed Nucleic Acid stain.

2.8. Interaction of metal complexes with HSA by Fluorescence Spectroscopy

The excitation wavelength was set to 295 nm, and the emission spectra were recorded at room temperature in the range of 300 to 450 nm. The fluorescence intensities of the metal compounds, the buffer and the DMSO are negligible under these conditions, and so is the effect of additions of pure DMSO on the fluorescence of HSA. An 8 mM solution of each compound in DMSO was prepared and ten aliquots of 2.5 µL were added successively to a solution of HSA (10 µM) in phosphate buffer (pH = 7.39), the fluorescence being measured 240 s after each addition. The data was analyzed using the classical Stern-Volmer equation $F_0/F = 1 + K_{SV}[Q]$.

2.9. Interaction of metal complexes 3 and 4 with HSA by Isothermal Titration Calorimetry

The HSA and titrant solutions were prepared in phosphate buffer (pH = 7.39) and degassed prior to titration. In a standard experiment, the protein (5µM) was titrated with the metal complex solution (1.5–3 mM) by a series of 34 successive injections of 7 µL each, with an interval of 240 s between injections. A background titration of titrant solution into buffer was subtracted from each experimental titration to account for heat of dilution. The data was analyzed with a two-site binding model using Origin 50 software supplied with the microcalorimeter. Equilibrium was reached after each addition of ligand to protein during the ITC titrations as evidenced by the return to baseline of the trace of microcalories heat released per unit time in the raw data collected for the binding experiments. Concentrations are not directly measured but calculated based upon the starting total protein concentration and the actual titration curve generated from the integrated heat released for each injection of ligand solution of known concentration into the known volume of protein solution in the ITC cell.

2.10. Reversibility of binding to HSA by Circular Dichroism

The interaction of complexes **3** and **4** with HSA was studied by CD spectroscopy in the visible region (300–550 nm) in phosphate buffer (pH = 7.39). 2 mL samples of 1.12×10^{-4} M HSA were incubated at 37 °C for 20 h with increasing amounts of compound **3–4** (1–7 eq); the interaction was monitored by the appearance of a band in the visible region at 360 nm for **3** and 395 nm for **4**. All spectra were corrected by subtraction of a blank consisting of a solution of drug in buffer at the appropriate concentration for each sample. For binding reversibility studies, to a 2 mL sample of saturated HSA-**3** or HSA-**4** incubated previously for 20 h at 37 °C, was added either 20 µL of concentrated HCl to reach pH 4.00 or the appropriate amount of a 60 mM solution of citric acid in the same buffer to reach a 1:3 complex:chelator ratio. The CD spectra were recorded in the visible region after 1 and 20 hours.

3. Results and discussion

3.1. Synthesis, characterization and stability of the new compounds

The ligand **1** and metallic compounds (**2–3**) can be obtained in moderate to high yields following the procedure depicted in Scheme 1. All the new compounds (**1–4**) were fully characterized (see Experimental) and are air-stable red (**2**), orange (**3**) and yellow (**4**) solids.

The structure of cationic Au compound **2** was confirmed by IR (bands that can be assigned to anionic ClO_4^-), conductivity measurements (1:1 electrolyte) and high resolution mass spectrometry. The stabilities of the ligand and the complexes were evaluated by $^{31}\text{P}\{^1\text{H}\}$ and ^1H NMR spectroscopy in deuterated solvents and mixtures of deuterated solvents. Ligand **1** is soluble in H_2O , and solvents such as DMSO and CHCl_3 . It is stable in DMSO solution at RT for 14 days whereas in H_2O it is stable for 3 h.

The cationic Au derivative **2** is soluble in CH_3CN and DMSO and insoluble in chlorinated solvents, Et_2O , most non-polar organic solvents and H_2O . At room temperature it is stable in CH_3CN solution for 24 h while it decomposes in DMSO solution after 4 h. In a mixture 50:50 DMSO: H_2O compound **2** decomposes after 30 min to phosphine oxide $\text{TPA}=\text{O}$ and to compound **5** (equation 1). Compound **5** (containing deprotonated uninegative bidentate ligand picolinamide) had been previously reported as a cytotoxic agent against MOLT-4 (human leukemia) and C2C12 (mouse myoblast cancer) cell lines [25]. Neutral complexes **3** and **4** are soluble in DMSO in which they are stable for over 7 days and they are also stable in mixtures 50:50 DMSO: H_2O for over 4 days. Compounds **2**, **3** and **4** are soluble at micromolar concentration in mixtures 1:99 DMSO: H_2O or DMSO:buffer.

The crystal structures of **3** and **4** (Structure of **3** in Fig. 2) were compared to the molecular structures obtained by means of density functional calculations (see Experimental and Supplementary Material). Selected bond lengths and angles are collected in Table 1 and in Table S2. The geometry about the Pd(II) and Pt(II) centers is pseudo-square planar with the N(2)-M(1)-N(1) angle of $80.86(8)^\circ$ (Pd **3**) and $80.4(3)^\circ$ (Pt **4**) suggesting a rigid 'bite' angle of the chelating ligand. The Pd and Pt centers are on an almost ideal plane with negligible deviations from the least-squares plane. The coordination plane for Pd and Pt and the metallocyclic plane are only slightly twisted to give an angle of 2.6° (**3**) and 2.4° (**4**) between them. The main distances M-N(1) or M-N(iminic) and M-N(2) found for **3** and **4** are very similar to those found in related iminophosphorane complexes like $[\text{Pd}\{\text{k}^2\text{-C}_6\text{H}_4(\text{PPh}_2=\text{NC}_6\text{H}_4\text{Me-4'})\text{-2}\}\{\mu\text{-OAc}\}]_2$, $[\text{Pd}\{\text{k}^2\text{-C}_6\text{H}_4(\text{PPh}_2=\text{NC}_6\text{H}_4\text{Me-4'})\text{-2}\}(\text{tmeda})]\text{ClO}_4$ [29], $[\text{Pd}(\text{C}_6\text{H}_4\text{CH}_2\text{NMe}_2)(\text{Ph}_3\text{PNC}(\text{O})\text{-2-NC}_5\text{H}_4)]\text{ClO}_4$ [30] and $[\text{PtCl}(\text{PMe}_2\text{Ph})\{(\text{N}(\text{p-Tol})=\text{PPh}_2)_2\text{CHCH}_3\}]\text{Cl}$ [31]. We were unable to get crystals from the Au(III) compound **2** useful for a single crystal X-ray diffraction study but we got good estimates for its structural parameters from density functional calculations (see Table 1 and Table S2).

The molecular structure of the cation in the Au(III) compound **2** is depicted in Fig. 3. Like in the Pd(II) and Pt(II) complexes **3** and **4**, the metal center is in a pseudo-square planar arrangement (N(2)-Au(1)-N(1) angle of 80.62°). The distances calculated for Au-N(1) (Au-N(iminic)) and Au-N(2) (Au-N(pyridine)) and Au-Cl are in the range of those found for related complexes like $[\text{Au}(\text{Ph}_2\text{PyP}=\text{NC}(\text{O})\text{Ph})\text{Cl}_2]\text{ClO}_4$ [18] and those obtained for previously described compound **5** $[\text{AuCl}_2(\text{HN-C}(\text{O})\text{-2-NC}_5\text{H}_4)]$ [25]. The longer distances P-N(1) of $1.700 \text{ \AA}$ and N(1)-C(1) of $1.392 \text{ \AA}$ in **2** (compared to those in **3** and **4**) are indicative of a greater delocalized charge density [30] than in neutral Pd and Pt compounds (**3** and **4**). This may be the cause for the lower stability of compound **2** in water or in polar solvents compared to complexes **3** and **4**.

Frequencies of selected normal vibrational modes were also determined by DFT methods (Table S2) for the optimized structures of compounds **2-4**. The calculated and the experimental frequencies of M-Cl and P=N and C=O stretching modes are in reasonable agreement [32].

3.2. Cytotoxicity Studies

Cytotoxicity results for ligand **1** and the new metallic compounds (**2–4**) are collected in Table 2. Values for the decomposition products of ligand **1** and compound **2** (the phosphine oxide TPA=O and gold compound **5**, Equation 1) are also collected for comparison purposes. The cytotoxicity (by a modification of the MTT-reduction method, see Experimental) was evaluated against two selected cell lines: human Jurkat-T acute lymphoblastic leukemia cells and DU-145 human prostate cancer cells. Cells were incubated in the presence of the compounds for 24 h. The sensitivity of T-cell leukemia Jurkat cells to compounds cisplatin, **1–5**, and T-PA=O was compared to that of normal T-lymphocytes (PBMC). Compound **3** (Pd) was less cytotoxic than cisplatin for Jurkat cells but Pt (**4**) and Au compounds **2** and **5** were two (**4**), seven (**5**) or even eleven (**2**) times more cytotoxic than cisplatin (Table 2). The IC₅₀ values displayed by the gold compounds are similar to that reported for an organogold(III) iminophosphorane complex described by us (**b** in Figure 1 [16]) to Jurkat leukemia cells (0.2 µM) and CLL (B-cell chronic lymphocytic leukemia cells) derived from patients; 60 nM to 100 nM [15]. Compound **5** was reported to have an IC₅₀ value of 3.1 µM for MOLT-4 human leukemia cell line [25]. All compounds were less toxic to PMBC than to T-Jurkat cell lines. The compounds were twelve (**2**), ten (**3**) or seven times (**4**, **5**) less toxic to the normal lymphocytes than to the leukemia cell line. However we have found here that cisplatin is 70 times less toxic to PMBC than to Jurkat cell lines.

The cytotoxicity to the DU-145 human prostate cancer cell line was evaluated and while Pd (**3**) was less cytotoxic than cisplatin for this cell line, the Pt (**4**) compound (65.3 µM) had an IC₅₀ value similar to that of cisplatin (79.2 µM). Au compounds **2** and **5** were more cytotoxic (17.4 µM (**2**) and 19.9 µM (**5**), 4.5 and 4 times more cytotoxic than cisplatin). The value obtained for compounds **2** and **5** is in line with values obtained with heterometallic Ti-Au₂ complexes recently described by our lab (14–27 µM) with a live imaging method after 24 h [33].

In addition, the cytotoxicity of ligand **1** and its decomposition product phosphine oxide TPA=O is notably low in all cell lines studied having IC₅₀ values greater than 500 µM. This indicates that the cytotoxic effect is due to the metal complex and that the cytotoxicity on the cancer cell lines follows the order Au>Pt>Pd for the metal center. Compound **2** decomposes quickly in solution to compound **5** and therefore the IC₅₀ values obtained for both derivatives are very similar.

Preliminary results on the cell death pathway caused by complexes **2–5** showed an inhibition of cell growth in the period studied (24 h) in DU-145 human prostate cancer cells. The morphology of the cells is very similar to that of the controls (Fig. 4, selected examples Au (**5**) and Pt (**4**) compounds), with neither signs of nuclear condensation nor chromatin fragmentation. Also, DU-145 showed not phosphatidylserine exposure or membrane permeabilization (Fig. 5), confirming that compounds **4** and **5** do not induce cell death in DU-145 at 24 h. In contrast, analysis of nuclear morphology revealed that compounds **4** and **5** induced cell death in Jurkat cells. Both apoptotic, condensed and fragmented nuclei, and necrotic, swollen nuclei were observed (Fig. 4). Flow cytometry after AnnexinV-APC/7-AAD staining (Fig. 5) confirmed that a significant percentage of cells were necrotic (7-AAD⁺ cells, upper right quadrant). Thus the mode of action of the gold compound [AuCl₂(HN-C(O)-2-NC₅H₄)] **5** and new hydrophilic iminophosphorane platinum complex **4** in Jurkat cells seems different from that of cisplatin (which is via apoptosis) [34]. It is estimated that about 1% of intracellular cisplatin binds to DNA primarily by forming intrastrand cross-links between adjacent purines [3, 35] and triggers the DNA-damage response that activates canonical apoptotic pathways [36].

We found that iminophosphorane gold(III) complexes **a** and **b** (Fig. 1) induced both necrosis and apoptosis and that the necrotic cell death induced by **a** and **b** was Bax/Bak- and caspase-independent [15]. We demonstrated that compounds **a** and **b** act mainly through ROS generation that leads to necrosis [15]. Similarly, compounds **4** and **5** seem to induce both necrotic and apoptotic cell death in Jurkat leukemia cells. Necrotic cell death that we observed in a fraction of cells could correspond to necroptosis, a “programmed” necrosis, since it has been demonstrated by others that ROS accumulation can be implicated in this type of cell death [37].

The activity of compounds **3–5** and cisplatin against apoptosis-resistant cells was also tested (Fig. S1). Multidomain proapoptotic proteins Bax and Bak are essential for the onset of mitochondrial permeabilization and apoptosis through the intrinsic pathway. Interestingly, we observed that compounds **4** and **5** exhibited some toxicity to Jurkat sh-Bak cells (Bax/Bak-deficient Jurkat cells) similar to previous results with (compounds **a** and **b** in Fig. 1) [15]. This could be an advantage over cisplatin, whose activity is totally dependent on the presence of functional Bax and Bak.

3.3. Interaction with DNA

Since DNA replication is a key event for cell division, it is among critically important targets in cancer chemotherapy. Most cytotoxic platinum drugs form strong covalent bonds with the DNA bases [38, 39]. However, a variety of platinum compounds act as DNA intercalators upon coordination to the appropriate ancillary ligands [40]. There are also reports on palladium derivatives interacting with DNA in covalent [41, 42] and noncovalent ways [43–45]. While most gold(III) and gold(I) compounds display reduced affinity for DNA [9, 15, 16], gold(I)-phosphine derivatives with weakly bound ligands (such as halides) bind in a nondenaturing fashion to DNA [35, 46]. DNA conformational alterations can be detected by means of circular dichroism spectroscopy [37]. When Calf Thymus DNA is incubated with increasing amounts of Au derivative (**5**), a slight decrease (Fig. 6) of the intensities of the negative and especially the positive bands are observed, indicating a decrease in helicity (destabilizing effect) [47]. Those changes in the stacking and the helicity of CT DNA at low drug:nucleotide ratios ($r = 0.1/0.5$) are probably related to electrostatic effects or to the ability of the compounds to intercalate DNA. Similar CD spectra were observed with other cationic square-planar gold(III) compounds with N- containing ligands such as $[\text{Au}(\text{phen})\text{Cl}_2]\text{Cl}$ or $[\text{AuCl}(\text{terpy})]\text{Cl}_2$ [48]. Au(III) complexes structurally related to compound **5** derived from aminoquinoline such as $[\text{Au}(\text{Quinpy})\text{Cl}]\text{Cl}$, $[\text{Au}(\text{Quingly})\text{Cl}]\text{Cl}$ and $[\text{Au}(\text{Quinala})\text{Cl}]\text{Cl}$ were proposed to interact by intercalation, although no CD spectra were provided [49].

In contrast, when CT DNA is incubated for 20h with increasing amounts of Pd (**3**), and particularly Pt (**4**) there are not noticeable changes at low DNA-drug ratios (up to $r = 0.5$ or even 1 for **4**) and only at ratios of 1 is there a small increase of the positive band indicating a small stabilizing effect most plausibly by electrostatic effects (Fig. S2).

We also performed agarose gel electrophoresis studies on the effects of compounds **3–5** on plasmid (pBR322) DNA (Fig. 7). This plasmid has two main forms: OC (open circular or relaxed form, Form II) and CCC (covalently closed or supercoiled form, Form I).

Changes in electrophoretic mobility of both forms are usually taken as evidence of metal-DNA binding. Generally, the larger the retardation of supercoiled DNA (CCC, Form I), the greater the DNA unwinding produced by the drug [50]. Binding of cisplatin to plasmid DNA, for instance results in a decrease in mobility of the CCC form and an increase in mobility of the OC form (see lanes a, b and c for cisplatin in Fig. 7) [51]. Treatment with increasing amounts of ligand **1** does not cause any shift for either form, consistent with no

unwinding or other change in topology under the chosen conditions. Treatment with increasing amounts of compounds **3–5** retards the mobility of the faster-running supercoiled form (Form I) especially at high molar ratios. Similar patterns of mobility have been described for some Pt(IV) complexes in the presence of glutathione as reducing agent [51]. In these cases, although the resulting Pt(II) products bind to closed circular DNA, their effect in the mobility of Form I (or CCC) DNA is different from that produced by cisplatin [51]. These results are in agreement with the small stabilizing effects observed in the interaction of the Pd (**3**) and Pt (**4**) compounds with calf thymus DNA by CD spectroscopy. These effects are different from those observed in the CD spectra of cisplatin and other Pd and Pt derivatives which bind in covalent cis-bidentate fashion to DNA [33].

In conclusion, the experiments probing DNA-drug interactions showed that new Pd (**3**) and Pt (**4**) IM complexes do not interact strongly with Calf Thymus DNA at physiological pH *in vitro* and that gold compound (**5**) interacts more strongly with DNA most likely by intercalation. All the complexes interact with plasmid (pBR322) DNA, most plausibly in a way different from that of cisplatin.

3.4. Interaction with HSA

Human serum albumin is the most abundant carrier protein in plasma and is able to bind a variety of substrates including metal cations, hormones and most therapeutic drugs. It has been demonstrated that the distribution, the free concentration and the metabolism of various drugs can be significantly altered as a result of their binding to the protein [52]. HSA possesses three fluorophores, these being tryptophan (Trp), tyrosine (Tyr) and phenylalanine (Phe) residues, with Trp214 being the major contributor to the intrinsic fluorescence of HSA. This Trp fluorescence is sensitive to the environment and binding of substrates or changes in conformation that can result in quenching. Quenching can occur by two different mechanisms, a dynamic mechanism caused by diffusional collisions between the protein and the quencher, and a static mechanism resulting from the formation of a non fluorescent complex. The fluorescence spectra of HSA in the presence of increasing amounts of **3–5** and cisplatin were recorded in the range of 300–450 nm upon excitation of the tryptophan residue at 295 nm. The compounds caused a concentration dependent quenching of fluorescence without changing the emission maximum or shape of the peaks, as seen in Fig. 8 for compound **3**. The fluorescence data was analyzed by the Stern-Volmer equation. While a linear Stern-Volmer plot is indicative of a single quenching mechanism, either dynamic or static, the positive deviation observed in the plots of F_0/F versus $[Q]$ of our compounds (Fig. 8) is indicative of the presence of different binding sites in the protein. These binding sites may have naturally different affinities for the quencher, or the effects may be due to changes in the conformation of the protein after initial interactions that expose new binding sites previously inaccessible to the quencher [53]. In this graph higher quenching by the iminophosphorane complexes and **5** was observed compared to that of cisplatin under the chosen conditions. This is probably an indication of the faster hydrolysis in aqueous solution of our compounds compared to that of cisplatin. The interaction of cisplatin and related compounds with HSA have been studied by a variety of analytical techniques [52] and despite varying the techniques and conditions (such as incubation time, initial concentration of protein, drug:protein ratio and the nature of incubation medium) there seems to be a common strong and irreversible binding of cisplatin to HSA most plausibly to methionine and histidine residues [54].

In an attempt to gather more information about the nature of the interaction between the iminophosphorane complexes and HSA, isothermal titration calorimetry (ITC) experiments were carried out. This sensitive tool allows for a complete characterization of the thermodynamics of drug binding. ITC has been used for the study of the interaction of Ni^{2+}

[55], Co^{2+} [56], Er^{3+} [57] and Ru^{2+} -chloroquine [58] compounds with HSA but to our knowledge, the binding of palladium or platinum compounds has not been assessed with this technique. The data obtained from the titrations (illustrated in Fig. 9 for complex **3**) were best fitted to a model of two sequential binding sites with different affinities for the drug. A sequential binding model was required to fit the data based upon the very large errors in fits using a single site, and the excellent fit to data using 2 sites. The errors are obtained from the iterated fitting routines provided in the software for the ITC apparatus such that the quality of fits can be evaluated both visually and from parameters like errors in K_D and n , and X-squared values (see experimental section). The thermodynamic parameters for the interaction of compounds **3** and **4** with the protein are collected in Table 3 with K_1 of $(5.29 \pm 0.87) \times 10^4$ (**3**) and $(1.43 \pm 0.13) \times 10^4$ (**4**). The first binding site has a binding affinity approximately 40 times larger than the second one for both Pd(II) and Pt(II) complexes ($[1.41 \pm 0.04] \times 10^3$ **3** and $[371.6 \pm 20.05]$ **4**), hence the sequential interaction. Binding constant values for other metal ions (Ni^{2+} [55], Co^{2+} [56], Er^{3+} [57]) or metal complexes (Ru^{2+} [58]) binding to HSA are also in the mM to microM range.

The ITC results may explain the lack of linearity observed in the fluorescence quenching studies, as the Stern-Volmer method assumes all binding sites to be equivalent. Unfortunately, ITC experiments with the gold(III) compound **5** could not be performed due to poor solubility at the required concentrations. Similarly, experiments with cisplatin did not yield useful data. The slow hydrolysis of the chloride ligands requires incubation of the drug with the protein for several hours or days [52], which is incompatible with the ITC technique.

Attempts to correlate the K_a of a drug with the percentage plasma protein binding have been carried out [59, 60]. The first binding constant for the Pt compound (**4**) $(1.43 \pm 0.13) \times 10^4$ is correlated with a roughly 90% plasma protein binding which is considered the upper limit for effective chemotherapeutics (values higher than 90% are considered to be disadvantageous). More important however, is to assess if this binding can be reversed. If the interaction to HSA is too strong, the drug might not be able to reach the cellular target. Reversibility can be achieved by contact with a low pH environment, as in tumor tissues, or by chelators present in the cytosol that may displace the amino acids in typical HSA-metallodrug complexes. We studied the reversibility of the binding of HSA to compounds **3** and **4** by CD spectroscopy. The protein was first titrated with compounds **3** and **4**, achieving saturation with 4 and 6 equivalents respectively as determined by the appearance and increase in intensity of a visible band at 360 nm for **3** (negative) and 395 nm for **4** (positive) in their CD spectra (Fig. 10a and S3a).

By using a metal ion chelator like citric acid, a decrease of the intensity of the visible bands was observed, especially in the case of platinum compound **4**, with a 50% reduction after only 1 hour of incubation with a 3-fold excess of the chelating agent (Fig. 11b). The effect of citric acid on the HSA-**3** adduct was less significant with only a 12% decrease after the same period of time (Fig. S3b). Decreases of 25–30% in the same conditions were achieved with arene-Ru(II)-chloroquine antimalarial and antitumor agents whose binding to HSA was considered reversible [58]. In a different experiment with our new complexes, the pH of the buffered solutions was decreased from 7.40 to 4.00 by addition of HCl. An effect on the spectrum of the HSA-**4** adduct was observed again, by the decrease of the visible band intensity of 52% after 1 hour (Fig. 11c), while the CD spectrum of the HSA-**3** adduct showed large shifts and shape modifications of the visible band but no genuine indication of the Pd center being released from the protein (Fig. S3c). A decrease of 18%–40% after 96 h incubation was achieved with the previously described arene-Ru(II)-chloroquine derivatives whose binding to HSA was reversed by a decrease of pH [58]. Thus, we propose that the reversibility of the binding **4** to HSA by chelators present in the cytosol and/or contact with

a low pH environment is possible. However, for the Pd (**3**) complex, some permanent bands were seen after long incubation in the presence of citrate (Fig. S3b) or at low pH (Fig. S3c) that could reflect modification of HSA by this metal. Therefore, no evidence for release (reversibility) was seen using CD spectroscopy for the Pd (**3**) derivative.

4. Conclusion

We have prepared new hydrophilic iminophosphorane complexes of d⁸ metals. While we did not get stable gold(III) complexes containing the water-soluble ligand reported here, Pd(II) and Pt(II) complexes were stable in the used conditions for biological experiments. The cytotoxicity, cell death pathway and reactions with DNA and HSA of the gold(III) compound were due to the generation of a cytotoxic decomposition product [AuCl₂(HN-C(O)-2-NC₅H₄)] **5**, previously reported. The Pd compound (**3**) was found to be less cytotoxic than cisplatin and to have a related mode of action. We found that the Pt(II)-iminophosphorane coordination derivative (**4**) was more cytotoxic than cisplatin to leukemia cell lines (both T-Jurkat and cisplatin-resistant Jurkat sh-Bak). **4** showed higher toxicity against leukemia cells when compared to normal human T-lymphocytes or PBMC and its cell death pathway seems to be different from that of cisplatin. Interestingly, this compound did not interact strongly with CT DNA. It was shown that its interaction with plasmid (pBR322) DNA (binding to CCC or Form I) is different from that of cisplatin. It was demonstrated that it interacted with HSA in a moderate and reversible way which may be an advantage to the antitumor activity of this complex *in vivo*. These and previous results obtained in our laboratories warrant further studies on iminophosphorane complexes of gold(III) and platinum(II) as anticancer agents.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the financial support of a grant from the NIH-National Institute of General Medical Sciences (NIGMS), SC2GM082307 (M.C.) and a grant from the Spanish Ministry of Science and Innovation SAF2010-14920 (I.M.). We thank Prof. Andrzej Jarzecki (Brooklyn College) for his help with the DFT calculations of compounds **2–4** and students Farrah Benoit and Malgorzata Frik for their assistance with some fluorescence measurements. We also thank Dr. Esteban P. Urriolabeitia for helpful discussions on the synthesis of ligand **1**.

Abbreviations

ABB	annexin binding buffer
7-AAD	7-Amino-Actinomycin
CD	circular dichroism
COD	cyclooctadiene
CT	calf thymus
DFT	density functional theory
DMSO	dimethyl sulphoxide
EDTA	ethylenediaminetetraacetic acid
FCS	fetal calf serum
Hepes	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid

HQuinala	N-(8-quinolyl)alanine-carboxamide
HQuinpy	N-(8-quinolyl)pyridine-2-carboxamide
HSA	human serum albumin
ITC	isothermal titration calorimetry
mTOR	mammalian target of rapamycin
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
phen	1,10-phenantroline
PS	phosphatidylserine
ROS	reactive oxygen species
TAE	tris-acetate/EDTA buffer
tert-BuDAD	N,N'-bis(2,6-diisopropylphenyl)2,3-butanediimine
terpy	2,2',6',2''-terpyridine
THF	tetrahydrofuran
tmeda	N,N,N',N''-tetramethylethylenediamine
TMRE	tetramethylrhodamine ethyl ester
TPA	1,3,5-triaza-7-phosphaadamantane

References

1. Thayer AM. Platinum drugs take their toll. *Chem. Eng. News*. 2010; 88(26):24–28.
2. Kelland L. *Nat Rev Cancer*. 2007; 7:573–584. [PubMed: 17625587]
3. Sava G, Bergamo A, Dyson PJ. *Dalton Trans*. 2011; 40:9069–9075. and refs. therein. [PubMed: 21725573]
4. Dhar, S.; Lippard, SJ. Current status and mechanism of action of platinum-based drugs. Ch 3. In: Alessio, E., editor. *Bioinorganic Medicinal Chemistry*. Wiley-VCH; 2011. p. 79-96.
5. Wang, X.; Guo, XZ. New trends and future developments of platinum-based antitumor drugs. Ch 4. In: Alessio, E., editor. *Bioinorganic Medicinal Chemistry*. Wiley-VCH; 2011. p. 97-149.
6. Aleman J, del Solar V, Alvarez-Valdes A, Rios-Luci C, Padron JM, Navarro-Ranninguer C. *MedChemComm*. 2011; 2:789–793. and refs. therein.
7. Berners-Price SJ. *Angew. Chem. Int. Ed*. 2011; 50:804–805.
8. Farrer NJ, Woods JA, Salassa L, Zhao Y, Robinson KS, Clarkson G, Mackay FS, Sadler PJ. *Angew. Chem. Int. Ed*. 2010; 49:8905–8908.
9. Berners-Price, SJ. Gold-based therapeutic agents. A new perspective. Ch 7. In: Alessio, E., editor. *Bioinorganic Medicinal Chemistry*. Wiley-VCH; 2011. p. 197-222.
10. Serrano FA, Matsuo AL, Monteforte PT, Bechara A, Smaili SS, Santana DP, Rodrigues T, Pereira FV, Silva LS, Machado J Jr, Santos EL, Pesquero JB, Martins RM, Travassos LR, Caires ACF, Rodrigues EG. *BMC Cancer*. 2011; 11:296–311. and refs. therein. [PubMed: 21756336]
11. Olzewski U, Clafey J, Hogan M, Tacke M, Zeillinger R, Bednarski P, Hamilton G. *Invest. New Drugs*. 2011; 29:607–614. and refs. therein. [PubMed: 20162321]
12. de Oliveira Silva D. *Anti-Cancer Agents in Med. Chem*. 2010; 10:312–323. and refs. therein.
13. Shyder SD, Fu Y, Habtemariam A, van Rijt SH, Cooper PA, Loadman PM, Sadler PJ. *Med. Chem. Comm*. 2011; 2:666–668. and refs. therein.
14. Gasser G, Ott I, Metzler-Nolte N. *J. Med. Chem*. 2011; 54:3–25. and refs. therein. [PubMed: 21077686]

15. Vela L, Contel M, Palomera L, Azaceta G, Marzo I. *J. Inorg. Biochem.* 2011; 105:1306–1313. [PubMed: 21864808]
16. Shaik N, Martinez A, Augustin I, Giovinazzo H, Varela A, Aguilera R, Sanaú M, Contel M. *Inorg. Chem.* 2009; 48:1577–1587. [PubMed: 19146434]
17. Kilpin KJ, Henderson W, Nicholson BK. *Inorg. Chim. Acta.* 2009; 362:3669–3676.
18. Brown SDJ, Henderson W, Kilpin KJ, Nicholson BK. *Inorg. Chim. Acta.* 2007; 360:1310–1315.
19. Aguilar D, Contel M, Urriolabeitia EP. *Chem. A. Eur J.* 2010; 16:9287–9296. 2010.
20. Aguilar D, Contel M, Navarro R, Soler T, Urriolabeitia EP. *J. Organomet. Chem.* 2009; 694:486–493.
21. Aguilar A, Contel M, Navarro R, Urriolabeitia EP. *Organometallics.* 2007; 26:4604–4611.
22. van Berkel SS, van Eldijk MB, van Hest JCM. *Angew. Chem. Int. Ed.* 2011; 50:8806–8827.
23. Bittner S, Assaf Y, Krief P, Pomerantz M, Ziemnicka BT, Smith CG. *J. Org. Chem.* 1985; 50:1712–1718.
24. Drew D, Doyle JR, Shaver AG. *Inorg. Synth.* 2007; 13:47–55.
25. Fang D, Yang CT, Randford JD, Vittal JJ. *Dalton Trans.* 2003:4749–4753.
26. Frisch, MJ.; Trucks, GW.; Schlegel, HB.; Scuseria, GE.; Robb, MA.; Cheeseman, JR.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, GA.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, HP.; Izmaylov, AF.; Bloino, J.; Zheng, G.; Sonnenberg, JL.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, R.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, JA.; Peralta, JE., Jr; Ogliaro, F.; Bearpark, M.; Heyd, JJ.; Brothers, E.; Kudin, KN.; Staroverov, VN.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, JC.; Iyengar, SS.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, JN.; Klene, M.; Knox, JE.; Cross, JB.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, RE.; Yazyev, O.; Austin, AJ.; Cammi, R.; Pomelli, C.; Ochterski, JW.; Martin, RL.; Morokuma, K.; Zakrzewski, VG.; Voth, GA.; Salvador, P.; Dannenberg, JJ.; Dapprich, S.; Daniels, AD.; Farkas, Ö.; Foresman, JB.; Ortiz, JV.; Cioslowski, J.; Fox, DJ. *Gaussian 09, Revision A.1.* Wallingford CT: Gaussian, Inc.; 2009.
27. Lopez-Royuela N, Perez-Galan P, Galan-Malo P, Yuste VJ, Anel A, Susin SA, Naval J, Marzo I. *Biochem Pharmacol.* 2010; 79:1746–1758. [PubMed: 20188077]
28. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. *Cancer Res.* 1988; 48:589–601. [PubMed: 3335022]
29. Vicente J, Abad JA, Clemente R, Lopez-Serrano J, Ramirez de Arellano MC, Jones PG, Bautista D. *Organometallics.* 2003; 22:4248–4259.
30. Falvello LR, Gracia MM, Lazaro I, Navarro R, Urriolabeitia EP. *New J. Chem.* 1999:227–235.
31. Avis MW, Elsevier CJ, Veldman N, Kooijman H, Spek AL. *Inorg. Chem.* 1996; 35:1518–1528. [PubMed: 11666367]
32. Baker J, Jarzecki AA, Pulay P. *J. Phys. Chem. A.* 1998:1412–1424.
33. González-Pantoja JF, Stern M, Jarzecki AA, Royo E, Robles-Escajeda E, Varela-Ramírez A, Aguilera RJ, Contel M. *Inorg. Chem.* 2011; 50:11099–11110. and refs. therein. [PubMed: 21958150]
34. Elie BT, Levine C, Ubarretxena-Belandia Iban, Varela A, Aguilera R, Ovalle R, Contel M. *Eur. J. Inorg. Chem.* 2009:3421–3430. and refs. therein.
35. Natile G, Arnesano F. *Coord. Chem Rev.* 2009; 253:2070–2081. and refs. therein.
36. Siddik ZH. *Oncogene.* 2003; 22:7265–7279. [PubMed: 14576837]
37. Thapa RJ, Basagoudanavar SH, Nogusa S, Irrinki K, Mallilankaraman K, Slifker MJ, Beg AA, Madesh M, Balachandran S. *Mol Cell Biol.* 2011; 14:2934–2946. [PubMed: 21576359]
38. Caradonna JP, Lippard SJ, Gait MJ, Singh M. *J. Am. Chem. Soc.* 1982; 104:5793–5795.
39. Dabrowiak, JC. *Metals in medicine.* John Wiley and Sons; 2009.
40. Liu HK, Sadler PJ. *Acc. Chem. Res.* 2011; 44:349–359. [PubMed: 21446672]
41. Ruíz J, Cutillas N, Vicente C, Villa MD, López G, Lorenzo J, Avilés FX, Moreno V, Bautista D. *Inorg. Chem.* 2005; 44:7365–7376. [PubMed: 16212362]
42. Gao E, Zhu M, Liu L, Huang Y, Wang L, Shi S, Chuyue ZW, Sun Y. *Inorg. Chem.* 2010; 49:3261–3270. [PubMed: 20199051]

43. Quiroga AG, Pérez JM, López-Solera I, Masaguer JR, Luque A, Roman P, Edwards A, Alonso C, Navarro-Ranninger C. *J. Med. Chem.* 1998; 41:1399–1408. [PubMed: 9554873]
44. Mansouri-Torshizi H, I-Moghaddam M, Divsalar A, Saboury AA. *Biorg. Med. Chem.* 2008; 16:9616–9625.
45. Paul AK, Mansouri-Torshizi H, Srivastava TS, Chavan SJ, Chitnis MP. *J. Inorg. Biochem.* 1993; 50:9–20. [PubMed: 8473884]
46. Blank CE, Dabrowa JC. *J. Inorg. Biochem.* 1984; 21:21–29. [PubMed: 6547163]
47. Cutts SM, Masta A, Panousis C, Parsons PG, Sturm RA, Phillips DR. *Drug- DNA Interact. Protocols.* 1997; 90:95–106.
48. Messori L, Orioli P, Tempi C, Marcon G. *Biochem. Biophys. Res. Commun.* 2001; 281:352–360. [PubMed: 11181054]
49. Yang T, Tu C, Zhang J, Lin L, Zhang X, Liu Q, Ding J, Xu Q, Guo Z. *Dalton Trans.* 2003:3419–3424.
50. Sherman SE, Lippard SJ. *Chem Rev.* 1987:1153–1181.
51. Shi Y, Liu SA, Kerwood DJ, Goodisman J, Dabrowiak JC. *J. Inorg. Biochem.* 2012; 107:6–14. [PubMed: 22169035]
52. Timerbaev AR, Hartinger CG, Aleksenko SS, Keppler BK. *Chem. Rev.* 2006; 106:2224–2248. [PubMed: 16771448]
53. Lacowicz, JR. *Principles of Fluorescence Spectroscopy.* Springer; 2006. Ch 8; p. 238-266.
54. Ivanov AI, Christodoulou J, Parkinson JA, Barnham KJ, Tucker A, Woodrow J, Sadler PJ. *J. Biol. Chem.* 1998; 273:14721–14730. [PubMed: 9614070]
55. Saboury AA, *Chem J. Thermodynamics.* 2003:1975–1981.
56. Sokolowska M, Wszelaka-Rylik M, Poznański J, Bal W. *J. Inorg. Biochem.* 2009:1005–1013. [PubMed: 19487034]
57. Rezaei Behbehani G, Divsalar A, Saboury AA, Faridbod F, Ganjali MR. *J. Therm. Anal. Cal.* 2009; 96:663–668.
58. Martínez A, Suálrez J, Shand T, Magliozzo RS, Sálncchez-Delgado RAJ. *Inorg. Biochem.* 2011:39–45.
59. Kratochwil NA, Huber W, Muller F, Kansy M, Gerber PR. *Biochem. Pharma.* 2002; 64:1355–1374.
60. Yan L, Wang X, Wang Y, Zhang Y, Li Y, Guo Z. *J. Inorg. Biochem.* 2012:46–51. [PubMed: 22112839]

Highlights for review

- Synthesis of the first water-soluble iminophosphorane(IM) ligand
- Preparation of Pt(II) and Pd(II) compounds stable in physiological media. Gold (III) compound decomposes to an stable N,N- cytotoxic gold(III) derivative
- Pt(II)-IM and N,N-Au(III) more cytotoxic than cisplatin to leukemia (cell death by necroptosis) and human prostate cancer cell lines and to cisplatin resistant leukemia cell lines, and less toxic to normal lymphocytes
- Pt(II) shows an interaction with DNA weaker and different than that of cisplatin
- All complexes interact with HSA faster than cisplatin (fluorescence spectroscopy) and the interaction of Pt(II) and Pd(II) complexes with HSA was evaluated for the first time by ITC (Isothermal Titration Calorimetry)
- Interaction of Pt(II) derivatives with HAS reversible by low pH or addition of a metal chelator (advantageous for their possible effects in vivo)

Fig. 1. Examples of selected iminophosphorane organogold(III) complexes with cytotoxic properties prepared by our group. [13] ROS production at the mitochondrial level was a critical step in the cytotoxic effect of these compounds. [13a]

Fig. 2. Molecular structure of the compound $[\text{PdCl}_2(\text{N,N-IM})]$ **3** with the atomic numbering scheme. The structure for compound $[\text{PtCl}_2(\text{N,N-IM})]$ **4** is identical and selected bond and angles for **3** and **4** are collected in Table 1.

Fig. 3. Optimized structure of the cation in [AuCl₂(N,N-IM)]ClO₄ (2) obtained from DFT calculations.

Fig. 4.

Compounds **3–5** induce apoptosis and necroptosis. Jurkat and DU-145 cells were cultured for 24 h in the presence of compounds **3–5** or left untreated. Nuclei were stained with Hoechst 333248 (10 µg/ml) and cells were photographed under UV light. The figure shows the images of controls and selected compounds **4** and **5**.

Fig. 5.

Jurkat cells (5×10^5 cells/ml) or DU145 cells (1×10^5 cells/ml) were treated for 24 h with compounds **4** or **5** (concentrations for IC₅₀ values). Apoptosis/necrosis hallmarks were analyzed by simultaneously measuring the exposure of phosphatidylserine and 7-Amino-Actinomycin D (7-AAD) uptake as described in the Experimental section. The percentage of cells in each region is indicated.

Fig. 6. CD spectra of CT incubated for 24 h at 37 °C with Au derivative (**5**) at 0, 0.1, 0.25, 0.5 and 1 ratios.

Fig. 7.

Electrophoresis mobility shift assays for cisplatin and compounds **1**, **3–5** (see Experimental for details). DNA refers to untreated plasmid pBR322. *a*, *b*, *c* and *d* correspond to metal/DNA ratios of 0.25, 0.5, 1.0 and 2.0 respectively.

Fig. 8.

(a) Fluorescence titration curve of HSA with compound **3**. Arrow indicates the increase of quencher concentration. (b) Stern-Volmer plot for quenching with compounds **3–5** and cisplatin.

Fig. 9.
ITC titration of HSA with complex 3. Data was corrected for heat of dilution (see experimental).

Fig. 10.

a) CD spectra (visible region) of HSA with **4**. b) Effect of the addition of 15 equivalents of citric acid on the spectrum of the HSA-**4** complex over time. c) Effect of low pH on the spectrum of the HSA-**4** complex over time.

Scheme 1.

Synthesis of d⁸ metal coordination complexes containing new chelating ligand TPA=N-C(O)-2-NC₅H₄ (N,N-IM) **1**.

Equation 1.

Decomposition products of compound **2** in DMSO solution or a 50:50 mixture of DMSO:H₂O at RT after 4 hours or 30 min respectively.

Table 1

Selected structural Parameters of complexes **2–4** obtained from DFT calculations and the comparison with experimental values.^a Bond lengths in Å and angles in °. (Full table S2 in supplementary material)

	2		3		4	
	Calcd	Exp	Calcd	Exp	Calcd	Exp
M-N(1)	2.097 2.073 ^b	2.052(2)	2.112 2.083 ^b	2.058(6)	2.098 2.076 ^b	
M-N(2)	2.086 2.064 ^b	2.024(2)	2.069 2.049 ^b	2.004(7)	2.040 2.031 ^b	
M-Cl(1)	2.304 2.321 ^b	2.2943(8)	2.311 2.349 ^b	2.300(2)	2.326 2.358 ^b	
M-Cl(2)	2.301 2.309 ^b	2.2922(8)	2.329 2.342 ^b	2.299(2)	2.339 2.354 ^b	
P-N(1)	1.700 1.694 ^b	1.658(2)	1.663 1.678 ^b	1.661(7)	1.667 1.681 ^b	
N(1)-C(1)	1.392 1.390 ^b	1.373(3)	1.377 1.378 ^b	1.366(11)	1.379 1.379 ^b	
N(1)-M-N(2)	80.62 80.84 ^b	80.86(8)	79.54 80.59 ^b	80.4(3)	79.64 80.39 ^b	
Cl(1)-M-Cl(2)	88.88 88.30 ^b	88.74(3)	90.52 88.86 ^b	88.17(9)	89.46 87.92 ^b	

^aGaussian 09 program package (see Experimental), calculated in gas phase.

^bCalculated in PCM aqueous solution (see Experimental).

Table 2

IC₅₀ (μM) of cisplatin, ligand **1**, phosphine oxide TPA=O and metal complexes **2–5** complexes in human cell lines. All compounds were dissolved in 1% of DMSO and diluted with water before addition to cell culture medium for a 24 h incubation period. Cisplatin was dissolved in water.

	Jurkat	PBMC	DU-145
Cisplatin	7.4±2.1	500±18	79.2±15.8
TPA=O	>500	>500	>500
1	>500	>500	>500
2	0.66±0.07	7.9±2.9	17.4±5.1
3	19.6±2.6	213±22	301±27
4	3.5±0.7	23.4±0.9	65.3±7.0
5	0.97±0.4	7.3±3.3	19.9±1.7

Table 3Thermodynamic parameters obtained from ITC experiments for compounds **3** and **4**.

	3	4
K_1 (M^{-1})	$(5.29 \pm 0.87) \times 10^4$	$(1.43 \pm 0.13) \times 10^4$
ΔH_1 (Kcal/mol)	$(-1.06 \pm 0.16) \times 10^4$	$(-4.69 \pm 0.41) \times 10^4$
ΔS_1	-14.00	-138.2
K_2 (M^{-1})	$(1.41 \pm 0.04) \times 10^3$	371.6 ± 20.05
ΔH_2 (Kcal/mol)	$(-3.96 \pm 0.08) \times 10^5$	$(-1.89 \pm 0.10) \times 10^6$
ΔS_2	-1313	-6321